Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.

Julie L BatistaAli HaririManish MaskiSusan RichardsBadari GudivadaLewis A RaynorElvira PonceChristoph WannerRobert J Desnick

Published in: Clinical kidney journal (2024)

Agalsidase beta treatment preserves kidney function and delays progression to severe clinical events among adult patients with FD. Plasma GL-3 levels analysed in paediatric patients showed normalization of elevated pre-treatment levels in most patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
emergency department
early onset
patient reported outcomes
left ventricular
patient reported
data analysis